High Tumor Burden Follicular Lymphoma
Showing 1 - 25 of >10,000
Follicular Lymphoma, Tumor Trial in Houston (Obinutuzumab, CC-99282)
Not yet recruiting
- Follicular Lymphoma
- Tumor
-
Houston, TexasM D Anderson Cancer Center
Oct 30, 2023
Diffuse Large B Cell Lymphoma, Follicular Lymphoma Grade 3B Trial in Changchun (R-CDOP)
Recruiting
- Diffuse Large B Cell Lymphoma
- Follicular Lymphoma Grade 3B
- R-CDOP
-
Changchun, Jilin, ChinaThe First Bethune Hospital of Jilin University
Sep 15, 2021
Follicular Lymphoma Trial in Germany (Copanlisib, Obinutuzumab)
Recruiting
- Follicular Lymphoma
-
München, Bavaria, Germany
- +39 more
May 19, 2022
Indolent Non-Hodgkin Lymphoma Trial in München (Ibrutinib, GA 101)
Active, not recruiting
- Indolent Non-Hodgkin Lymphoma
- Ibrutinib
- GA 101
-
München, Bavaria, GermanyKlinikum der Universität München
May 6, 2021
Follicular Lymphoma Trial in Italy (Immunochemo regimen: Rituximab-bendamustine (Arm A), Immunochemo regimen:
Recruiting
- Follicular Lymphoma
- Immunochemotherapy regimen: Rituximab-bendamustine (Arm A)
- +9 more
-
Barletta, Barletta Andria Trani, Italy
- +68 more
Oct 13, 2022
Mantle Cell Lymphoma, Ketogenic Dieting Trial in New York (Ketogenic Diet)
Recruiting
- Mantle Cell Lymphoma
- Ketogenic Dieting
- Ketogenic Diet
-
New York, New YorkWeill Cornell Medicine
Oct 17, 2022
B-Cell Non-Hodgkin Lymphoma, DLBCL, Not Otherwise Specified, High Grade B-Cell Lymphoma Trial in Seattle (Acalabrutinib,
Recruiting
- B-Cell Non-Hodgkin Lymphoma
- +7 more
- Acalabrutinib
- Axicabtagene Ciloleucel
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Dec 9, 2022
Non-hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma Trial in Boston (CD79b-19 CAR T cells,
Not yet recruiting
- Non-hodgkin Lymphoma
- +9 more
- CD79b-19 CAR T cells
- +2 more
-
Boston, MassachusettsMassachusetts General Hospital
Sep 6, 2023
Cohort Studies Trial in Jinan (apantamide+docetaxel+ADT, apantamide+ADT treatment)
Recruiting
- Cohort Studies
- apantamide+docetaxel+ADT
- apantamide+ADT treatment
-
Jinan, Shandong, ChinaQilu hospital
Feb 3, 2023
Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma Trial in Atlanta (drug, biological,
Recruiting
- Grade 1 Follicular Lymphoma
- +7 more
- Acalabrutinib
- +3 more
-
Atlanta, GeorgiaEmory University Hospital/Winship Cancer Institute
Dec 7, 2021
Aggressive B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage III Grade 3 Follicular
Recruiting
- Aggressive B-Cell Non-Hodgkin Lymphoma
- +19 more
- CD47 Antagonist ALX148
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Aug 9, 2022
Follicular Lymphoma Trial in France (Rituximab IV, Rituximab SC)
Completed
- Follicular Lymphoma
- Rituximab IV
- Rituximab SC
-
Aix En Provence, France
- +49 more
Jan 9, 2023
Chronic Lymphocytic Leukemia (CLL), Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL) Trial (Routine care as per
Not yet recruiting
- Chronic Lymphocytic Leukemia (CLL)
- +5 more
- Routine care as per site standard.
- (no location specified)
Sep 15, 2023
Cardiovascular Events Among Adults Relapsed or Refractory
Recruiting
- Recurrent Aggressive B-Cell Non-Hodgkin Lymphoma
- +9 more
- Electronic Health Record Review
-
Houston, TexasM D Anderson Cancer Center
Dec 5, 2022
Follicular Lymphoma Trial in Saint Louis (biological, drug, procedure)
Suspended
- Follicular Lymphoma
- Personalized tumor vaccine
- +6 more
-
Saint Louis, MissouriWashington University School of Medicine
Nov 9, 2021
Adult Grade III Lymphomatoid Granulomatosis, Cutaneous B-cell Non-Hodgkin Lymphoma, MALT Trial in Duarte (biological, procedure,
Active, not recruiting
- Adult Grade III Lymphomatoid Granulomatosis
- +23 more
- autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells
- +2 more
-
Duarte, CaliforniaCity of Hope Medical Center
Jan 4, 2023
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Trial in Nanjing (6-month course of antiandrogen drugs, Long-term course of
Recruiting
- Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
- 6-month course of antiandrogen drugs
- Long-term course of antiandrogen drugs
-
Nanjing, Jiangsu, ChinaUrology dpt, First Affiliated Hospital of Nanjing Medical Univer
Jul 13, 2023
Refractory Diffuse Large B-cell Lymphoma, Refractory DLBCL, Not Otherwise Specified, Recurrent DLBCL Trial in Duarte, Saint
Recruiting
- Refractory Diffuse Large B-cell Lymphoma
- +4 more
-
Duarte, California
- +2 more
Aug 9, 2022
B Cell Lymphoma, Aggressive Lymphoma, Diffuse Large B Cell Lymphoma Trial in Saint Louis (Mosunetuzumab)
Recruiting
- B Cell Lymphoma
- +5 more
-
Saint Louis, MissouriWashington University School of Medicine
Jan 3, 2023
Large B-cell Lymphoma, DLBCL, Not Otherwise Specified, Primary Mediastinal Large B-cell Lymphoma (PMBCL) Trial (Epcoritamab)
Available
- Large B-cell Lymphoma
- +4 more
- Epcoritamab
- (no location specified)
Feb 16, 2023
Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between DLBCL and Classic Hodgkin Lymphoma, Recurrent
Not yet recruiting
- Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma
- +21 more
- Biopsy
- +8 more
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Apr 7, 2023
Lymphoma, B-Cell, Relapsed Cancer, Refractory Lymphoma Trial in Boston (Adaptive Bridging Radiation Therapy (ABRT))
Not yet recruiting
- Lymphoma, B-Cell
- +7 more
- Adaptive Bridging Radiation Therapy (ABRT)
-
Boston, MassachusettsDana-Farber Cancer Institute
Aug 16, 2023
Refractory Aggressive B-cell Lymphomas, Refractory B-Cell Non-Hodgkin Lymphoma, Aggressive B-cell NHL Trial in Boston
Not yet recruiting
- Refractory Aggressive B-cell Lymphomas
- +12 more
- ACALABRUTINIB
- +2 more
-
Boston, Massachusetts
- +1 more
Oct 13, 2022
Recurrent DLBCL, Recurrent Grade 3b Follicular Lymphoma, Recurrent High Grade B-Cell Lymphoma Trial in Duarte (Biopsy,
Not yet recruiting
- Recurrent Diffuse Large B-Cell Lymphoma
- +11 more
- Biopsy
- +5 more
-
Duarte, CaliforniaCity of Hope Medical Center
Jan 3, 2023